JP2023552180A - 放射性核種錯体のための安定な製剤 - Google Patents

放射性核種錯体のための安定な製剤 Download PDF

Info

Publication number
JP2023552180A
JP2023552180A JP2023532682A JP2023532682A JP2023552180A JP 2023552180 A JP2023552180 A JP 2023552180A JP 2023532682 A JP2023532682 A JP 2023532682A JP 2023532682 A JP2023532682 A JP 2023532682A JP 2023552180 A JP2023552180 A JP 2023552180A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ascorbic acid
composition according
sodium ascorbate
radiolabeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552180A5 (enExample
Inventor
マルクス，ゼバスティアン
ライプ，オリヴァー
ヒームズ，ルーク
マリア アンドレオリ，エレナ
Original Assignee
アイティーエム ソルツィン ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイティーエム ソルツィン ゲーエムベーハー filed Critical アイティーエム ソルツィン ゲーエムベーハー
Publication of JP2023552180A publication Critical patent/JP2023552180A/ja
Publication of JP2023552180A5 publication Critical patent/JP2023552180A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023532682A 2020-11-25 2021-11-24 放射性核種錯体のための安定な製剤 Pending JP2023552180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2020/083363 WO2022111800A1 (en) 2020-11-25 2020-11-25 Stable formulations for radionuclide complexes
EPPCT/EP2020/083363 2020-11-25
PCT/EP2021/082812 WO2022112323A1 (en) 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes

Publications (2)

Publication Number Publication Date
JP2023552180A true JP2023552180A (ja) 2023-12-14
JP2023552180A5 JP2023552180A5 (enExample) 2024-12-04

Family

ID=73598128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532682A Pending JP2023552180A (ja) 2020-11-25 2021-11-24 放射性核種錯体のための安定な製剤

Country Status (8)

Country Link
US (2) US20240374732A1 (enExample)
EP (1) EP4251213A1 (enExample)
JP (1) JP2023552180A (enExample)
KR (1) KR20230134472A (enExample)
CN (1) CN116806144A (enExample)
AU (1) AU2021388832A1 (enExample)
CA (1) CA3171753A1 (enExample)
WO (2) WO2022111800A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2023164769A1 (en) * 2022-03-02 2023-09-07 Point Biopharma, Inc. Radiopharmaceutical and methods
US20250099634A1 (en) 2023-09-25 2025-03-27 Novartis Ag Method of treating cancer
US12343409B1 (en) * 2024-06-05 2025-07-01 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
WO2025255398A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
CN120733077B (zh) * 2025-09-01 2025-12-05 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
US10756278B2 (en) 2017-07-18 2020-08-25 Purdue Research Foundation In situ thermal control of langmuir-schaefer transfer
US20200030466A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONTRAST MEDIA & MOLECULAR IMAGING, vol. Vol.2017, Article ID8160134, JPN6025048067, 2017, pages 1 - 12, ISSN: 0005855807 *

Also Published As

Publication number Publication date
AU2021388832A1 (en) 2023-06-08
US20240374732A1 (en) 2024-11-14
US12605447B2 (en) 2026-04-21
WO2022111800A1 (en) 2022-06-02
WO2022112323A1 (en) 2022-06-02
CA3171753A1 (en) 2022-06-02
KR20230134472A (ko) 2023-09-21
CN116806144A (zh) 2023-09-26
US20250170243A1 (en) 2025-05-29
EP4251213A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US12605447B2 (en) Stable formulations for radionuclide complexes
JP7436512B2 (ja) 腎保護物質としてのパラアミノ馬尿酸（ｐａｈ）
EP4065176B1 (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
CN107438615B (zh) 用于制备放射性核素络合物的方法和试剂盒
AU2018207190A1 (en) Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
CA3171718C (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2804349C2 (ru) Парааминогиппуровая кислота (паг) как вещество для защиты почек
HK40078095B (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095A (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2025218931A1 (en) Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
Schweinsberg Novel 99mTc-labeled bombesin analogues with improved pharmacokinetics for targeting of gastrin-releasing-peptide receptor-positive tumors
HK40065088B (en) Para-aminohippuric acid (pah) as a renal protective substance
HK40065088A (en) Para-aminohippuric acid (pah) as a renal protective substance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260512